Treatment of endometrial stromal tumors

Berchuck, Andrew; Rubin, Stephen C.; Hoskins, William J.; Saigo, Patricia E.; Pierce, Virginia K.; Lewis, John L.

doi:10.1016/0090-8258(90)90109-x

Cited by 154 publications

(59 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…113 Adjuvant RT in ESS has been shown to reduce local recurrence rates but again with limited effect on survival. 114,115 Because of concerns about radiation exposure, frequent routine asymptomatic surveillance imaging is no longer recommended for young women after primary therapy for ESS.…”

Section: Evaluation and Primary Therapymentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Section: Evaluation and Primary Therapymentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

“…9 Surgery is also advocated for debulking of recurrence and for residual tumours after pelvic radiation and chemotherapy. 2,[8][9][10]12 Oophorectomy serves the purpose of removing the trophic production of oestrogen in pre-menopausal patients. In one study, there was 100% recurrence in patients who retained their ovaries versus 43% in those who had them removed.…”

Section: Surgerymentioning

confidence: 99%

“…Undifferentiated endometrial sarcomas have a pleomorphic appearance, marked cytological atypia and high mitotic activity (>10 mitotic figures/10hpf) with atypical mitotic figures. [8][9][10][11] They tend to grow rapidly and metastasise early, and are generally fatal. Disease-free survival and prognosis are substantially better for low-grade versus undifferentiated sarcomas.…”

mentioning

confidence: 99%

Hormonal Treatment of Metastatic Endometrial Stromal Sarcomas

Kitayama¹,

Shimizu²,

Terada³

2011

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

Uterine sarcomas in general are rare: they account for 4% of all uterine malignancies. [1][2][3][4] Endometrial sarcomas account for 10-15% of all uterine sarcomas. They make up fewer than 1% of all gynaecological malignancies. 1,2,5,6 The reported incidence is approximately one to two cases per million women in the US. 6,7 Women often present with an enlarged uterus or have complaints of heavy menstrual bleeding.Occasionally, the diagnosis is established by endometrial biopsy or diagnostic curettage. Most often, however, the diagnosis is not recognised until the time of hysterectomy. Generally, these women are pre-or peri-menopausal at the time of diagnosis. AbstractEndometrial sarcomas account for 10-15% of all uterine sarcomas. These tumours are composed of uniform cells that resemble the stromal cells of proliferative endometrium. As endometrial sarcomas are rare, accounting for less than 1% of all gynaecological malignancies, there is an absence of clinical trials and treatment guidelines do not exist. It is well-known that low-grade endometrial stromal sarcomas (LGESS) are often oestrogen-receptor-(OR) and progesterone-receptor-(PR) positive. This provides a potential target for treatment, similar to other hormonally sensitive tumours. This article reviews the literature in terms of current management strategies for LGESS, particularly the data in terms of hormonal therapy. KeywordsEndometrial stromal sarcoma, uterine sarcoma, mesenchymal tumours, hormone therapy, progestins

show abstract

“…39 In leiomyosarcoma, the removal of ovaries does not appear to influence survival, and the preservation of ovarian tissue in premenopausal women does not increase the risk of recurrence. 37,38,40 Lymph node resection is controversial. For all histological types, suspicious nodules with increased size should be submitted for biopsy.…”

mentioning

confidence: 99%

“…15 The roles of cytoreduction, lymphadenectomy, conservation of the ovaries -in young patients -for the preservation of fertility and adjuvant treatment are controversial in these tumors and vary with histology, staging, and patient age. 37,38 Because endometrial stromal sarcoma is an estrogendependent tumor, similar to type I endometrial cancer, a bilateral salpingo-oophorectomy is recommended, even for premenopausal women presenting stage I disease. High recurrence rates were found among women who preserved their ovaries (50%) compared with those who did not (4%).…”

mentioning

confidence: 99%

Clinical and molecular features of uterine sarcomas

Almeida¹,

Cunha²,

Maciel³

et al. 2014

Medical Express

View full text Add to dashboard Cite

INTRODUCTION: Uterine sarcomas are rare forms of malignant neoplasm, comprising about 3% of all malignant uterine tumors, representing less than 1% of all gynecologic malignancies. Low cure rates often occur due mainly to distant metastases, usually to the lungs. Aggressiveness, high rates of local recurrence, distant metastasis and poor prognosis with overall two-year survival less than 50% are common features of uterine sarcomas. Despite the low prevalence, these tumors are of great interest because of their multiple morphological and clinical features. OBJECTIVE: This article will be focused on the uterine sarcomas general aspects, etiology, prognosis, treatment and molecular features. METHOD: This review was performed using the Pubmed database to search for published articles. RESULTS: Little is known about the etiology of uterine sarcomas. Some studies have demonstrated the association between genetic events involving mutations in genes of the cell cycle and apoptosis and epigenetic in gynecologic sarcomas. Previous studies showed that chromosomal translocations have been identified, resulting in fusion genes that are constitutive and might involve the activation of transcription factors. Advances in molecular techniques have improved the diagnostic possibilities and allowed an improved understanding of the various pathologies. CONCLUSIONS: There are several factors that make the study of sarcomas a challenging issue, since those tumors are rare and the cell origin of each histologic type is nor well known Thus, molecular study of the events involved in the development of different types of cancer may lead to new strategies used in the diagnosis and treatment of these tumors.

show abstract

Treatment of endometrial stromal tumors

Cited by 154 publications

References 6 publications

Uterine Neoplasms

Uterine Neoplasms

Hormonal Treatment of Metastatic Endometrial Stromal Sarcomas

Clinical and molecular features of uterine sarcomas

Contact Info

Product

Resources

About